Solara Active Pharma Sciences Limited (BOM:890202)
India · Delayed Price · Currency is INR 308.70
+35.20 (12.87%)
At close: Apr 1, 2026
BOM:890202 Revenue
In the fiscal year ending March 31, 2026, Solara Active Pharma Sciences had annual revenue of 13.69B INR with 6.64% growth. Solara Active Pharma Sciences had revenue of 3.87B in the quarter ending March 31, 2026, with 41.86% growth.
Revenue
13.69B
Revenue Growth
+6.64%
P/S Ratio
1.98
Revenue / Employee
7.71M
Employees
1,775
Market Cap
27.13B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 13.69B | 852.20M | 6.64% |
| Mar 31, 2025 | 12.84B | -51.60M | -0.40% |
| Mar 31, 2024 | 12.89B | -1.55B | -10.73% |
| Mar 31, 2023 | 14.44B | 1.75B | 13.83% |
| Mar 31, 2022 | 12.68B | -3.49B | -21.56% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| IOL Chemicals and Pharmaceuticals | 23.19B |
| Neuland Laboratories | 20.23B |
| Shilpa Medicare | 15.39B |
| Bajaj HealthCare | 6.11B |
| NGL Fine-Chem | 5.01B |
| Sai Parenteral's | 3.81B |
| Anlon Healthcare | 1.72B |
| Gujarat Themis Biosyn | 1.66B |
Solara Active Pharma Sciences News
- 7 weeks ago - Solara Active Pharma share price jumps over 4% after USFDA closes Puducherry facility inspection with VAI status - Business Upturn
- 7 months ago - Solara Active Pharma’s Mangalore facility clears US FDA inspection with VAI classification - Business Upturn
- 8 months ago - Solara Active Pharma shares slump nearly 9% today after reporting Q2 net loss - Business Upturn
- 1 year ago - Solara Active Pharma shares rise 4% after Ambernath facility clears USFDA inspection with zero observations - Business Upturn
- 1 year ago - Solara Active Pharma shares down 5% as Managing Director Poorvank Purohit resigns - Business Upturn
- 1 year ago - Solara Active Pharma Sciences announces demerger of CRAMS and Polymers business - Business Upturn
- 1 year ago - Solara Active Pharma Sciences Q3 FY25 Results: Revenue up 41.6% YoY to Rs 300.31 crore - Business Upturn